Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14501426 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL3460266 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603335 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603406 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL13697136 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL3359938 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603391 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL14416499 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL1031687 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL1828824 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117545285-A | Method for stabilizing perovskite/hole transport layer interface through multidentate chelate biological material and preparation method of formal photovoltaic device | 重庆大学 | 2024-02-09 | — | — | CN | claimed |
| EP-2160397-B1 | A NOVEL AND HIGHLY STEREOSELECTIVE PROCESS FOR PREPARING GEMCITABINE AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2014-03-26 | — | — | EP | claimed |
| US-7214791-B2 | Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material | SHENZHEN HANDE TECHNOLOGY CO., LTD. (CN) | 2007-05-08 | — | — | US | claimed |
| US-20060003963-A1 | Method for preparation of 2'-deoxy-2', 2'-difluoro-beta-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-beta-D-glucose as raw material | HANDE PHARMA LIMITED (CN) | 2006-01-05 | — | — | US | claimed |
| EP-0577302-B1 | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates | LILLY CO ELI (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0577302-A1 | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | claimed |
| US-5256798-A | Treating beta-anomer ribofuranosyl sulfonate with source of conjugate anion | ELI LILLY AND COMPANY (US) | 1993-10-26 | — | — | US | claimed |
| CN-117545285-A | Method for stabilizing perovskite/hole transport layer interface through multidentate chelate biological material and preparation method of formal photovoltaic device | 重庆大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-112979723-B | Gemcitabine intermediate purification method | 江苏科本药业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112979724-B | Mother liquor recovery method of gemcitabine intermediate | 浙江外国语学院 | 2022-04-22 | — | — | CN | disclosed |
| US-9790252-B2 | 2-fluorinated riboses and arabinoses and methods of use and synthesis | CORNELL UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2318423-B1 | PROCESS FOR MAKING 5-AZACYTOSINE NUCLEOSIDES AND THEIR DERIVATIVES | SCINOPHARM TAIWAN LTD (TW) | 2014-05-07 | — | — | EP | disclosed |
| WO-2011003018-A9 | HALOGENATED 2-DEOXY-LACTONES, 2'-DEOXY--NUCLEOSIDES, AND DERIVATIVES THEREOF | CORNELL UNIVERSITY (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-0577302-A1 | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0577304-A1 | Stereoselective anion glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0577303-A1 | Stereoselective glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0576231-A1 | Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2, 2-difluoro-D-ribofuranosyl derivatives | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| EP-0576229-A1 | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2, 2-difluoro-D-ribofuranosyl sulfonates | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5256798-A | Treating beta-anomer ribofuranosyl sulfonate with source of conjugate anion | ELI LILLY AND COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| US-5252756-A | Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates | ELI LILLY AND COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003963-A1 | Method for preparation of 2'-deoxy-2', 2'-difluoro-beta-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-beta-D-glucose as raw material | DCTD, DPYD, RNGTT | CDA 16/4885PDE4D 803/4885PDE3A 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.